Recent Headlines
Bioo Scientific Corp. Receives NIH Grant for the Development of Novel Anti-Viral Therapeutics
Bioo Scientific received a $1.25 million grant from the National Institutes of Health to develop new anti-viral therapeutics. - May 07, 2009 - Bioo Scientific
ENCO Analytix, Inc, Announces Name Change to ENCO Pharmaceutical Development, Inc.
ENCO Analytix, Inc. announced today that effective immediately the company name will change to ENCO Pharmaceutical Development, Inc. - May 03, 2009 - Enco Pharmaceutical Development, Inc.
Bioo Scientific Launches In Vivo siRNA Delivery Reagent
Bioo Scientific Developed MaxSuppressor In Vivo RNA-LANCEr II to Optimize in vivo RNAi. - May 01, 2009 - Bioo Scientific
World's Leading Scientists Meet to Examine Barriers for Stem Cell Therapies to Cure Spinal Cord Injury
Following President Barack Obama's decision to lift the ban on federal funding for embryonic stem cell research, medical and scientific experts will converge at the University of Georgia to discuss how recent advances in stem cell research can be translated into cures for spinal cord injuries. The... - March 31, 2009 - Bedford Stem Cell Research Foundation
Massachusetts Scientists Make Stem Cell Discovery
Cell Multiplication Controlled by a Surprising set of Genes. Stem cell researcher Dr. Ann Kiessling has discovered that early human embryo cells express CLOCK, and other circadian genes, that other human cells growing in laboratories did not. This was a surprise. According to Professor Jose Cibelli of Michigan State University, "This is a seminal paper. I am sure we will be referring back to it 10, 20 years from now." - March 30, 2009 - Bedford Stem Cell Research Foundation
MoBiTec GmbH, Germany, is Offering Photochromic Fluorescent Protein EosFP
The Green-to-Red switchable, photochromic Fluorescent Protein „EosFP“ offers advantageous applications in Molecular Cell Biology, and is now available through the German biotech company MoBiTec GmbH. With violet light, single cells in an EosFP marked (green) cell population can be switched to red, so that their fate can be followed selectively, for example in embryonic cell differentiation. Alternatively, a particular compartment within an EosFP marked (green) cell can be switched to red. - March 25, 2009 - MoBiTec GmbH
MoBiTec GmbH Closes Distribution Agreement for Lactococcus lactis Gene Expression System with NIZO Food Research
NIZO food research has developed a Gram positive gene expression system making use of Lactococcus lactis and its regulation mechanism for the production of the antibiotic peptide nisin, the NIsin Controlled gene Expression system (NICE). The NICE system is already used as a dedicated expression system by many labs all around the world. With NICE, MoBiTec expands its rich portfolio of non-E. coli based expression systems. - March 15, 2009 - MoBiTec GmbH
MDS Nordion to Host Physician Expert Teams from Banner Good Samaritan Medical Center and UNC School of Medicine at SIR 2009
MDS Nordion event information for the Society of Interventional Radiology 2009 Scientific Meeting. - March 07, 2009 - MDS Nordion
MDS Nordion to Demonstrate Improved TheraSphere® Administration System During SIR 2009
MDS Nordion event information for the Society of Interventional Radiology 2009 Scientific Meeting. - March 07, 2009 - MDS Nordion
Genescient and Kronos Announce Alzheimer's Disease Collaboration
Genescient Corporation and Kronos Science Laboratory will work together to analyze the Kronos Alzheimer's Case-Control Database, considered to be the finest Alzheimer's Disease genetic data set in the US. The companies hope to identify genes previously unrecognized genes that are involved in Alzheimer's Disease. - March 04, 2009 - Genescient Corporation
New Hope in Cancer Treatment for Dogs: PharmaCom BioVet’s Veterinary Oncology Treatment Centers
“We lost three of our Siberian Huskies …close family members, to cancer.” The Bertholds vowed, “We would spend the rest of our lives for the sake of our living dogs — in addition to all other dogs — attempting to find better, improved cancer treatments.” PharmaCom BioVet is truly “a union of compassion and technology.” - March 03, 2009 - PharmaCom BioVet
Anavex Appoints Leading Alzheimer's Disease Expert Dr. Mark Smith to Scientific Advisory Board
Anavex Life Sciences Corp. today announced the appointment of Dr. Mark A. Smith, Ph.D., FRCPath, to its scientific advisory board. - February 12, 2009 - Anavex Life Sciences Corp.
Clinical Trials in Russia. Year 2008.
On February 04, 2009 Synergy Research Group (SynRG), a Russia-based CRO, presented the English version of SynRG Orange Paper Year 2008, a regular analytical report on the clinical trial market in Russia. The report contains hundreds of figures as well as dozens of tables and pictures covering... - February 07, 2009 - Synergy Research Group
Anavex Scales Up Synthesis of Anavex 2-73 for Phase 1 Alzheimer’s Disease Study
Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB (“Syntagon”) for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is... - February 04, 2009 - Anavex Life Sciences Corp.
Researchers Create Smaller, Brighter Probe, Tailored for Clinical Molecular Imaging and Tumor Targeting
Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic. According to the investigators at Memorial Sloan-Kettering Cancer... - December 22, 2008 - Hybrid Silica Technologies Inc.
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer's Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology
Anavex Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper... - December 19, 2008 - Anavex Life Sciences Corp.
Anavex Presents Potent Neuroprotective Effects of Anavex 1-41 at Neuroscience 2008
Anavex Life Sciences Corp., a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society... - December 17, 2008 - Anavex Life Sciences Corp.
GeneThera Will Test Raw and Processed Milk for Johne’s Disease Due to Evidence Linking Johne’s Disease to Irritable Bowel Syndrome (IBS) and Chron’s Disease
GeneThera will test raw and processed milk for Johne’s disease due to evidence linking Johne’s disease to Irritable Bowel Syndrome (IBS) and Chron’s disease starting January, 2009. GeneThera, Inc. (GTHR.PK), GeneThera announces it will soon begin testing of raw and processed milk... - December 10, 2008 - GeneThera Inc.
Endometriosis Patients Demand Awareness, Research, and Better Treatments: Sufferers Share What Works and What Does Not
In light of performers Julianne Hough’s and Lacey Schwimmer’s recent disclosure, Endometriosis patients around the world are coming together online to anonymously compare symptoms & related conditions with one another, share treatment reviews, and make research discoveries for future cures. - November 05, 2008 - CureTogether
Patients Share Health Data, Become Researchers to Seek Cures for Their Conditions
CureTogether to Demonstrate at Health 2.0 Conference How Some Patients Are Responding to Inadequate Research by Doing It Themselves. - October 23, 2008 - CureTogether
BellBrook Labs Announces a Kinase/ATPase Assay That is "2" Sensitive
The Transcreener ADP2 FP Assay is a homogenous fluorescence polarization assay that enables the facile detection and screening of established drug targets including protein and lipid kinases as wells as emerging targets such as heat shock proteins and other ATPases. - October 15, 2008 - BellBrook Labs
Utilising Cost Reduction Opportunities: Conference on "Optimising Stability Testing" in London
International experts discussed how to realise more efficient stability tests for medicinal products last Thursday and Friday (18 and 19 September) in London. At the two-day "Optimising Stability Testing" conference Dr Sven Oliver Kruse, managing director of Diapharm Analytics GmbH (www.diapharm.com), was one of those explaining how the burden of ongoing stability tests can be reduced with improved study design. - October 01, 2008 - Diapharm
Anavex Completes Successful Preclinical Studies on Lead Alzheimer's Drug Candidate
Anavex completes successful preclinical studies on Anavex 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease. - September 04, 2008 - Anavex Life Sciences Corp.
RemedyMD Promotes Adam Slovik as President and Chief Operating Officer
RemedyMD® Inc., pioneer in the use of predictive informatics to help improve medical outcomes, today announced the promotion of Adam Slovik to President and Chief Operating Officer. “Adam has all the tools and talent to succeed in this role,” said Gary Kennedy, RemedyMD chairman... - August 06, 2008 - RemedyMD Inc.
Anavex Presents Neuroprotective Effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008
Anavex Life Sciences presented its new findings of its ANAVEX 1-41 compound targeting Alzheimer's disease at ICAD (July 26 to 31, 2008). - August 02, 2008 - Anavex Life Sciences Corp.
Clinical Trials in Russia. 2nd Quarter 2008
On July 24, 2008 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analysis of the clinical trial market in Russia. The report contains hundreds of figures as well as dozens of tables and pictures covering various aspects of the Russian... - July 26, 2008 - Synergy Research Group
Korea's Largest Biotech Show Kicks Off in Osong
The 3rd BIO KOREA convention will be held from October 8th to 10th at Osong Bio-Technopolis. The event of this year offers a variety of high-level conference, international exhibition and partnership events and provide an opportunity to find business and technology partners. It expects to 350 companies and 25,000 visitors from all over the world. - July 17, 2008 - Bio Korea
Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA)
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) announces its participation at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA), where it will present results obtained with Anavex 1-41 demonstrating a protective effect against the neurotoxicity... - July 15, 2008 - Anavex Life Sciences Corp.
M-Scan Ltd Successfully Passes GMP Inspections by the FDA and UK MHRA
The world-leading provider of contract analytical services now conducts bio/pharmaceutical analysis to both GMP and GLP (compliant since 1992.) - July 04, 2008 - M-Scan
A Russian and Pakistani CRO Announce Alliance for Expansion of Global Clinical Trials Services
On June 30, 2008 Synergy Research Group (SynRG), a Russia-based CRO with more than 6-year experience in clinical trials in Russia announced the establishment of a new international CRO alliance with Metrics Research, a Pakistan-based CRO. This is the next step made by SynRG toward the formation of... - July 02, 2008 - Synergy Research Group
Xcelience Strengthens Development Services with Addition to Executive Team
The formulation development company’s services are led by an industry pioneer. - June 22, 2008 - Xcelience, LLC
Anavex Further Strengthens Board of Directors
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of David L. Tousley, CPA, MBA, to its Board of Directors. Mr. Tousley is an accomplished professional with many years of experience as a senior financial and operations executive in start-up and... - June 20, 2008 - Anavex Life Sciences Corp.
Clinical Trials in Russia. 1st Quarter 2008
On June 2, 2008 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analytical report on the market of clinical trials in Russia. According to the report The Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (alias RosZdravNadzor, RZN) approved 130 new clinical trials in Russia in Q1 2008. - June 04, 2008 - Synergy Research Group
Xcelience and Its CEO Are Finalists for Three Prestigious Business Awards
The Tampa-based CRO and its chief executive are voted as best company and CEO of the year. - May 26, 2008 - Xcelience, LLC
Anavex Announces Appointment of Oncology Specialist to Board of Directors, Changes to Executive Management
Anavex Life Sciences Corp. ("ANAVEX'') (OTC BB:AVXL.OB) today announced the appointment of Alison Ayers to its Board of Directors. Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer, with responsibility for Pfizer's oncology portfolio, which includes more than 20 drug... - May 23, 2008 - Anavex Life Sciences Corp.
Xcelience Launches New Service to Enhance Its Preformulation & Formulation Capabilities
The Tampa-based CRO continues its perpetual growth with new XRD support. - May 08, 2008 - Xcelience, LLC
Plymouth Pharmaceuticals and Dermatologist Cited in ‘Skin and Allergy News’ Regarding Drug’s (Acunol™) Role in Preventing Jewelry Allergy
The respected journal “Skin & Allergy News” recently released “Nickel Named Contact Allergen of the Year” in its current issue. Researcher Dr Katherine A Zug, of the Department of Dermatology at Dartmouth Hitchcock Medical Center in Lebanon, NH, has published her... - April 10, 2008 - Plymouth Pharmaceuticals Inc
Steriods on Barcode
Simple barcodes come of age. Immunoassays on barcodes seamlessly convey medical and drug abuse results, track patient progress and even alert patients of impending health problems. - March 20, 2008 - Prognosys LLC
Biopharma Innovators Syntaxin Wins Top Honours at 2007 Interactive Media Awards
Biopharma firm Syntaxin's new website has won a very prestigious IMA award which recognises great design, technical innovation and accessibility compliance within the interactive media industry. - March 19, 2008 - Syntaxin Ltd
Clinical Trials in Russia, 4th Quarter 2007
On February 18, 2008 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analytical report on the market of clinical trials in Russia. The report contains hundreds of figures as well as dozens of tables and pictures covering various aspects... - February 20, 2008 - Synergy Research Group
Xcelience Expands Its Early Drug Development Capabilities
The Tampa-based CRO is first to acquire next generation Xcelodose. - January 26, 2008 - Xcelience, LLC
Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008
Anavex Life Sciences Corp. achieved significant development of its lead drug candidates and growth of its management and scientific teams during 2007. - January 24, 2008 - Anavex Life Sciences Corp.
Anavex Strengthens Board of Directors
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL - News) announces the appointment of Dr. Cameron Durrant to its Board of Directors. - January 16, 2008 - Anavex Life Sciences Corp.
Anavex 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors
ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies. - January 16, 2008 - Anavex Life Sciences Corp.
Anavex Advances Drug Candidate for Treatment of Alzheimer's Disease
Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits. - January 16, 2008 - Anavex Life Sciences Corp.
NovaBay Pharmaceuticals Featured in November/December Issue of PharmaVOICE
Company Executives Offer “Crystal Ball” Predictions. VP of Research Discusses Need for New Approaches in Anti-Infectives. - November 22, 2007 - NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. Retains The Investor Relations Group of New York
IRG to Communicate the Company’s Clinical Development Programs - November 21, 2007 - NovaBay Pharmaceuticals, Inc.
Glycosan BioSystems Announces the Release of Extracel Sponge-96
Glycosan BioSystems launched its new product for cell-based assays Extracel Sponge-96. - November 15, 2007 - Glycosan BioSystems, Inc.
Clinical Trials in Russia, 3rd Quarter 2007
According to SynRG Orange Paper, in the 3rd Quarter 2007, the overall volume of the clinical trials in Russia and its basic parameters are generally the same as in the corresponding quarter of the last year. In the 3rd Quarter 2007 RosZdravNadzor (RZN) has issued 141 approvals for conducting new clinical trials, which is 2% more than in Q3 2006. - November 14, 2007 - Synergy Research Group
Xcelience’s Scientific Director Selected to Lead Key Sessions on Upcoming Conferences
Dr. Steve Bannister’s expertise requested for several speaking engagements over the next year - October 31, 2007 - Xcelience, LLC